ArticleHepatology international2022
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure.
Article in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A Novel Simplified Prognostic Model for 90-day Transplant-free Survival in Patients with Severe Acute Liver Injury/Acute Liver Failure.Journal of clinical and translational hepatology · 2026Article
- Risk factors analysis for progression to severe hepatitis in acute hepatitis E: a retrospective study of 146 hospitalized cases.BMC infectious diseases · 2025Article
- High Seroprevalence of Hepatitis E Virus Among Patients With Hepatitis B and Those With Hepatitis of Unknown Etiology in Central Vietnam.Open forum infectious diseases · 2025Article
- The predictive value of fibrosis profiles for hepatitis E virus-related liver failure among hospitalized patients with acute hepatitis E: a retrospective cohort study.BMC infectious diseases · 2025Article
- A case of thrombotic thrombocytopenic purpura induced by acute hepatitis E and successfully controlled by lymphoplasmapheresis plus rituximab.Virology journal · 2025Article
- Integrated Multi-Omic Analysis Reveals Causal Relationships and Causal Mechanisms of Peripheral Lymphocyte-Driven Remodeling in the Intrahepatic Immune Microenvironment of Early-Stage MAFLD.Journal of inflammation research · 2025Article
- Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention.Signal transduction and targeted therapy · 2024Article
- D-dimer-to-platelet count ratio as a novel indicator for predicting prognosis in HBV-related decompensated cirrhosis.Heliyon · 2024Article
- Development and validation of a machine learning model to predict prognosis in liver failure patients treated with non-bioartificial liver support system.Frontiers in medicine · 2024Article
- A case of acquired thrombotic thrombocytopenic purpura induced by acute severe hepatitis E: successfully treated by plasma exchange and rituximab.Thrombosis journal · 2023Article
- Platelets as a Gauge of Liver Disease Kinetics?International journal of molecular sciences · 2022Review
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Funding
Abstract
BACKGROUND AND
aimsHepatitis E virus-related acute liver failure (HEV-ALF) rapidly worsens and has a high mortality. However, no simple and specific parameters for predicting short-term mortality are available.
methodsA derivation cohort including 97 patients with HEV-ALF and another validation cohort were enrolled. Laboratory and clinical parameters were recorded. Platelet count, model for end-stage liver disease (MELD), and King's College criteria (KCC) were separately used for predicting mortality, and the levels of cytokines associated with systemic inflammation, platelet production, and platelet activation were measured.
resultsPlatelet counts were significantly lower in patients with HEV-ALF, and nonsurvivors had lower platelet counts than survivors (p < 0.001). Platelet count was an independent risk factor for predicting 28- and 90-day mortality in patients with HEV-ALF. The AUROC of the baseline platelet count (cutoff, 131 × 10
conclusionsDecreased platelet count is a simple and reliable indicator for predicting 28- and 90-day mortality in patients with HEV-ALF. Overactivation of platelets is an important risk for platelet counts decrease, and treatment aiming at platelet count recovery may be considered.
Indexed as
Identifiers
35229273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.